Spots Global Cancer Trial Database for Efficacy and Safety of Imatinib in Chordoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of Imatinib in Chordoma
Official Title: Phase II Study of Imatinib Mesylate in Chordoma
Study ID: NCT00150072
Conditions
Interventions
Study Description
Brief Summary: Preliminary response data, observed by Casali (Cancer, 2004) with imatinib 800 mg/day in patients affected by chordoma, need to be confirmed by a Phase II study, whose primary endpoint will be the formal assessment of clinical and pathological response. Aim of the study will be to explore treatment's activity, but also the potential impact of tumor response, the feasibility and outcome of subsequent surgery and radiotherapy. In addition, patterns of tumour response need to be investigated as well, given the peculiar patterns of response shown with molecular-targeted therapy in solid tumors.
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Aviano, , Italy
Novartis Investigative Site, Bologna, , Italy
Novartis Investigative Site, Candiolo, , Italy
Novartis Investigative Site, Firenze, , Italy
Novartis Investigative Site, Milano, , Italy
Novartis Investigative Site, Napoli, , Italy
Novartis Investigative Site, Padova, , Italy
Novartis Investigative Site, Pisa, , Italy
Novartis Investigative Site, Roma, , Italy
Novartis Investigative Site, Rozzano, , Italy
Novartis Investigative Site, Torino, , Italy
Novartis Investigative Site, Lausanne, , Switzerland
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
